German biotech startup AATec Medical announced that it has raised €4 million prior to a series A financing, with the funds going to development of the company’s ATL-105 inhaled recombinant alpha-1 antitrypsin (AAT) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). The funding came from the German Federal Agency for Disruptive Innovation (SPRIND) as well as individual investors, the company said.
According to AATec Medical, the company has already generated “robust” pre-clinical safety and efficacy data for the inhaled AAT and expects to initiate a Phase 1 trial of ATL-105 by next year. In 2023, AATec announced that it had partnered with Beurer for development of inhaled drug products, with Beurer developing and manufacturing the delivery devices.
AAtec CEO Rüdiger Jankowsky commented, “This funding is a crucial step toward preparing ATL-105 for clinical development. Non-CF bronchiectasis significantly impacts patients’ quality of life, and current treatment options are limited. We believe that ATL-105 has the potential to offer a meaningful therapeutic advance for millions of patients worldwide. In Western countries alone, more than 3 million patients suffer from NCFB. Thanks to our novel protein inhalation approach, ATL-105 is delivered directly to the lungs, maximizing therapeutic effectiveness at the primary site of inflammation and minimizing systemic side effects. The support from SPRIND validates our innovative approach and highlights the transformative potential of our technology.”
Read the AATec Medical press release
